Matinas BioPharma Holdings, Inc.
$0.55
▼
-0.64%
2026-04-21 08:17:01
www.matinasbiopharma.com
ASE: MTNB
Explore Matinas BioPharma Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.52 M
Current Price
$0.55
52W High / Low
$3.09 / $0.48
Stock P/E
—
Book Value
$1.09
Dividend Yield
—
ROCE
-202.13%
ROE
-1.67%
Face Value
—
EPS
$-2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
1.4
Debt / Equity
28.03
Current Ratio
2.79
Quick Ratio
2.79
Forward P/E
-0.17
Price / Sales
—
Enterprise Value
$0.56 M
EV / EBITDA
-0.08
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Stoke Therapeutics, Inc. | $36.46 | — | $2.16 B | — | -5.71% | -2.37% | $40.22 / $7.34 | $5.98 |
| 2. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 3. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 4. | Upstream Bio, Inc. | $9.99 | — | $543.66 M | — | -47.12% | -35.44% | $33.68 / $7.25 | $6.26 |
| 5. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 6. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 7. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.6 M | -1.58 M | -1.84 M | -1.95 M | -4.04 M | — |
| Net Profit | -1.91 M | -1.53 M | -5.25 M | -1.66 M | -8.43 M | — |
| EPS in Rs | -0.3 | -0.24 | -0.82 | -0.26 | -1.32 | -0.85 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 1.1 M | 3.19 M |
| Operating Profit | -6.96 M | -20.16 M | -23.77 M | -24.59 M |
| Net Profit | -10.35 M | -24.25 M | -22.94 M | -21 M |
| EPS in Rs | -1.61 | -3.79 | -3.58 | -3.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.21 M | 12.64 M | 25.1 M | 44.82 M |
| Total Liabilities | 2.38 M | 5.05 M | 5.86 M | 8.18 M |
| Equity | 4.83 M | 7.59 M | 19.25 M | 36.64 M |
| Current Assets | 4.08 M | 8.03 M | 15.54 M | 34.53 M |
| Current Liabilities | 1.46 M | 2.67 M | 2.62 M | 4.29 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.01 M | -15.88 M | -15.28 M | -19.16 M |
| Investing CF | 0.34 M | 9.21 M | 13.24 M | 4.88 M |
| Financing CF | 3.39 M | 9.17 M | -0.01 M | 0.08 M |
| Free CF | -7.01 M | -15.88 M | -15.5 M | -20.05 M |
| Capex | — | — | -0.22 M | -0.89 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -65.62% | — | — |
| Earnings Growth % | -5.71% | -9.26% | — | — |
| Profit Margin % | — | -2093.25% | -658.63% | — |
| Operating Margin % | — | -2168.43% | -771.33% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -2082.57% | -743.16% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-09-03 | 1:0.02 |